1443232-24-3

Upstream product

• 93102-05-7 N-benzyl-N-(methoxymethyl)-N-[(trimethylsilyl)methyl]amine 
• 251327-01-2 methyl (4R)-4-[(tert-butyloxycarbonyl)amino]cyclopent-1-ene-1-carboxylate 

Downstream Products

• 1443232-25-4 (3aR,5R,6aR)-methyl 2-benzyl-5-(tert-butoxycarbonylamino)octahydrocyclopenta[c]pyrrole-3a-carboxylate fumarate 
• 1557349-46-8 C₂₉H₃₃F₃N₄O₅ 
• 1537880-28-6 C₂₅H₂₇F₃N₄O₃ 
• 1537880-33-3 (3aR,5R,6aR)-benzyl 5-((3-methoxytetrahydro-2H-pyran-4-yl)amino)-3a-(3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,6-naphthyridine-6-carbonyl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate 
• 1537881-40-5 tert-butyl benzyl(((3aR,5R,6aR)-5-((tert-butoxycarbonyl)amino)-3a-(3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,6-naphthyridine-6-carbonyl)hexahydrocyclopenta[c]pyrrol-2(1H)-yl)sulfonyl)carbamate 
• 1537881-21-2 tert-butyl ((3aR,5R,6aR)-2-(benzylcarbamothioyl)-3a-(3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,6-naphthyridine-6-carbonyl)octahydrocyclopenta[c]pyrrol-5-yl)carbamate 
• 1537880-33-3 (3aR,5R,6aR)-benzyl 5-((3-methoxytetrahydro-2H-pyran-4-yl)amino)-3a-(3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,6-naphthyridine-6-carbonyl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate 
• 1537880-05-9 (3aR,5R,6aR)-benzyl 5-((tert-butoxycarbonyl)amino)-3a-(3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,6-naphthyridine-6-carbonyl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate 
• 1537880-03-7 (3aR,5R,6aR)-2-((benzyloxy)carbonyl)-5-((tert-butoxycarbonyl)amino)octahydrocyclopenta[c]pyrrole-3a-carboxylic acid 
• 1537880-01-5 (3aR,5R,6aR)-2-benzyl 3a-methyl 5-((tert-butoxycarbonyl)amino)hexahydrocyclopenta[c]pyrrole-2,3a(1H)-dicarboxylate 
• 1537882-66-8 tert-butyl ((3aR,5R,6aR)-2-phenyl-3a-(3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,6-naphthyridine-6-carbonyl)octahydrocyclopenta[c]pyrrol-5-yl)carbamate 

Relevant academic research and scientific papers

OCTAHYDRO-CYCLOPENTAPYRROLYL ANTAGONISTS OF CCR2

The present invention comprises compounds of Formula (I). Formula (I) wherein: R1, R2, R3, R4, R5, Z1 and Z2 are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

Discovery and SAR of 5-aminooctahydrocyclopentapyrrole-3a-carboxamides as potent CCR2 antagonists

SAR study of 5-aminooctahydrocyclopentapyrrole-3a-carboxamide scaffold led to identification of several CCR2 antagonists with potent activity in both binding and functional assays. Their cardiovascular safety and pharmacokinetic properties were also evalu

Chiral aminocyclopentene-based cycloaddition strategies to bicyclic [3.3.0] rings

Two cycloaddition methods were applied to chiral protected aminocyclopentenes 2 and 9 and provided novel bicyclic products 3 and 4 in good yields. The explanation for the observed stereochemistry was based on the sterically encumbered β-face forcing the c